Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harvard Bioscience (HBIO) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to $63.9 million.

  • Harvard Bioscience's Total Liabilities fell 302.35% to $63.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $63.9 million, marking a year-over-year decrease of 302.35%. This contributed to the annual value of $63.3 million for FY2024, which is 153.67% down from last year.
  • Latest data reveals that Harvard Bioscience reported Total Liabilities of $63.9 million as of Q3 2025, which was down 302.35% from $64.4 million recorded in Q2 2025.
  • In the past 5 years, Harvard Bioscience's Total Liabilities registered a high of $81.7 million during Q1 2022, and its lowest value of $61.7 million during Q2 2024.
  • For the 5-year period, Harvard Bioscience's Total Liabilities averaged around $70.0 million, with its median value being $67.5 million (2023).
  • Its Total Liabilities has fluctuated over the past 5 years, first soared by 1016.4% in 2022, then plummeted by 1319.03% in 2023.
  • Quarter analysis of 5 years shows Harvard Bioscience's Total Liabilities stood at $78.9 million in 2021, then decreased by 7.35% to $73.1 million in 2022, then decreased by 12.1% to $64.3 million in 2023, then decreased by 1.54% to $63.3 million in 2024, then grew by 0.98% to $63.9 million in 2025.
  • Its Total Liabilities stands at $63.9 million for Q3 2025, versus $64.4 million for Q2 2025 and $65.0 million for Q1 2025.